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ABSTRACT
DOUBLE-COATED BIODEGRADABLE POLY(BUTYL CYANOACRYLATE)
NANOPARTICULATE DELIVERY SYSTEMS FOR BRAIN TARGETING OF
DOXORUBICIN VIA ORAL ADMINISTRATION
Neeraj Kaushal

Primary brain cancer cells grow within the brain or cancer cells can metastasis
from different site of the body into brain. The major hurdle in the treatment of brain
cancer is the presence of blood-brain barrier (BBB). Additionally, acquired multidrugresistant (MDR) impedes the success of long-term chemotherapy. Therefore, the
objective of this investigation is to evaluate the brain targeting potential of orally
administered poly(butyl cyanoacrylate) nanoparticulate delivery systems (PBCA-NPDS),
double-coated with Tween 80 and polyethylene glycol (PEG) 20000 for brain delivery of
doxorubicin, that does not cross the BBB by itself. And, evaluate the MDR reversal
potential of PBCA-NPDS. Doxorubicin-loaded PBCA-NPDS were prepared by the
anionic polymerization method and were successively double-coated with Tween 80 and
PEG 20000 in varied concentrations. Brain uptake study of double-coated doxorubicinloaded PBCA-NPDS using bEnd.3 cell line suggested the role of clathrin-mediated
endocytosis in the uptake of double coated doxorubicin-loaded PBCA-NPDS. When
Transwell® permeable supports were used, significant transport of doxorubicin across the
cell monolayer was observed by the double-coated formulations, in comparison to
doxorubicin solution (p<0.05). Significant accumulation of doxorubicin in brain was
achieved after oral administration of double-coated doxorubicin-loaded PBCA-NPDS in
rats (p<0.05). Furthermore, simultaneously analyzing the pharmacokinetic data obtained
after intravenous and oral administrations, revealed the role of lymphatics in absorption

of double-coated doxorubicin-loaded PBCA-NPDS. When MDR reversal potential of
PBCA-NPDS was evaluated by cell uptake in P-gp overexpressing cell line, significant
uptake of doxorubicin was mediated by double-coated doxorubicin-loaded PBCA-NPDS
(p<0.05). These results were verified by MTT assay in P-gp or BCRP overexpressing cell
lines. MTT assays revealed that double-coated doxorubicin-loaded PBCA-NPDS
significantly potentiated the sensitivity of doxorubicin in P-gp overexpressing cells, in
comparison to doxorubicin solution, single-, and un-coated doxorubicin-loaded PBCANPDS (p<0.05 in all case), respectively. Further increase in concentration of Tween 80,
significantly enhanced the sensitivity of doxorubicin in BCRP overexpressing cell line, in
comparison to single- and double-coated doxorubicin-loaded PBCA-NPDS (with lower
concentration of Tween 80) (p<0.05 in all case). Hence, it could be concluded that
double-coated doxorubicin loaded PBCA-NPDS could be used for brain targeting of
doxorubicin administered orally and overcome MDR.
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1. Introduction
Malignant primary brain tumors are cancers that originate in the brain,
which typically grow faster than benign tumors and aggressively invade the
surrounding tissue. Although significant advances in terms of treatment using
operative techniques, radiotherapy, and adjuvant chemotherapy have been made,
the prognosis remains unfavorable. Even the adjuvant chemotherapy considered
to be effective for treatments of these malignant tumors, such as temozolomide,
the survival time of patients increases only marginally. In addition to this, such
treatment regimen poses intense adverse effects to healthy cells. Hence, there is a
need and opportunity for the growth of brain-targeted chemotherapy. However,
achieving drug delivery to the brain, remains a challenging task, due to the
presence of epithelia-like tight junction lining the brain capillary endothelium
referred to as the blood-brain barrier (BBB) (2).
To facilitate drug delivery across the BBB, number of approaches such as,
hyperosmotic disruption of the BBB (3), carrier systems like targeted antibodies
(4), prodrugs (Temodar®), liposomes (5), and nanoparticles (6–8) have been
explored. Among these approaches, surfactant coated nanoparticles have been
reported successfully to deliver drug across the BBB (6,8–12). The nanoparticles
coated with polysorbate 80 lead to the adsorption of apolipoprotein E from blood
plasma on the surface of nanoparticles, which then seem to mimic low-density
lipoprotein (LDL) which interacts with LDL receptor leading to their uptake by
the endothelial cells lining the BBB (13,14).
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2. Literature review
2.1. Brain tumors and doxorubicin
Brain tumors is a growth of tumor cells which occurs in the brain and can
be very heterogenous groups of tumors. Upon their diagnosis, subsequent
treatments such as radiation therapy or chemotherapy is initiated. Most of the
chemotherapeutics are administered via intravenous bolus leading to initial rapid
increase and subsequent decay of drug plasma concentrations (15). Tissue toxicity
as well as poor biopharmaceutical properties (i.e., protein binding, first-pass
metabolism, etc.) of these chemotherapeutic agents has led to number of attempts
to develop more rational formulations for chemotherapy (16).
As described previously, poor oral bioavailability of doxorubicin can be
partly attributed to over expression of the multidrug efflux transporter P-gp
(13,14) specifically of the intestinal lumen. The general approach to resolve this
problem would be to use P-gp inhibitors (i.e., cyclosporine A) to suppress
elimination process. However, these inhibitors suppress body’s immune system
and may lead to drug-drug interaction ultimately leading to medical
complications. Furthermore, these inhibitors are known to have their own sideeffects making it more difficult to incorporate in the drug delivery systems along
with chemotherapeutic agents (19). Recently, other approaches like advanced
targeted drug delivery systems have been studied extensively offering potential
alternatives to circumvent the aforementioned issues. Among which
biodegradable polymeric nanoparticles with brain targeting efficiency seems to be
one of the promising approaches for the development of oral chemotherapy with
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high patient compliance as well as improved therapeutic efficacy and reduced
adverse effects (7).
Among many properties of polymeric nanoparticles, the properties to
control drug release at a desired rate and to allow the provision of surface
modification with a homing device can be employed for desired drug release rate
and targeting to the brain. Covalent attachment apolipoprotein AI and B-100 to
albumin nanoparticles have shown to transport drug to the brain from systemic
circulation. Nevertheless, these surface modified nanoparticles takes an advantage
of the biochemical transport systems that are present in the BBB (20,21). Among
these systems, the LDL-receptor and the transferrin transcytosis systems may be
employed in the delivery of drugs.
2.2. Oral absorption of surface modified nanoparticles
Gastrointestinal (GI) tract, including oral cavity, the stomach, the small
intestine and the large intestine, is essentially a muscular tube lined by mucus
membrane. The stomach is primarily a secretory organ and its gastric acid
secretion and gastric emptying affect the drug absorption (22). However, these
aspects of gastric physiology have little relevance when considering uptake of
nanoparticulate delivery systems, owing to their size and specialized mechanism
for their uptake. In contrast, when considering the absorption of nanoparticles
from the intestine, specifically the small intestine, it is crucial to address the
mechanism in ileum (23,24). A specialized mechanism for the absorption of solid
lipid nutrients has been reported by Peyer. This absorption mechanism is related
to gut-associated lymphoid tissue (GALT) in the ileum, which is known as the
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Peyer’s patches. Due to the similarity between solid lipid and nanoparticles,
targeting nanoparticles to Peyer’s patches as a port of entry of nanoparticles in the
lymphatic circulation resulting in improved oral absorption. Schematic
representation of the mechanisms of gastrointestinal uptake of surface modified
nanoparticles [i.e., surface modified poly(butyl cyanoacrylate) nanoparticles] is
shown in Figure 1. Furthermore, accumulation in Peyer’s patches has been
reported to be govern by nanoparticle surface properties and size. Wherein, the
penetration being favored by nanoparticles with hydrophobic surfaces (25), and
particle size less than about 300 nm as in the case of polystyrene particles after
oral administration to rats (26).
Despite that three possibilities for uptake of nanoparticles have been
suggested (Figure 1). the simultaneous occurrence of more than one pathway has
been reported (27–30). The rapid appearance of orally administered nanoparticles
in the circulation (10 minutes post-dosing) can only be explained by the
paracellular pathway (28,31). Aprahamian et.al. (28) reported the presence of
nanoparticles in intercellular spaces (especially in larger defects of mucosa)
between 10-15 minutes after intraluminal injection into the intestine of
anesthetized Beagle dogs. After 15 minutes, the nanoparticles were already
observable in the lamina propria in proximity of the basal membrane of the
enterocytes. After 30 minutes, the nanoparticles were quite numerous at the
internal surface of the vascular epithelium where they generally formed clusters
and were noted to be in close contact with red cells. After 1 hour, very few

4

nanoparticles were found in the capillaries. Nanoparticles, although small in
numbers, were also present in the lymph ducts in the core of the villus.
In one of the reported work, Sanders and Ashworth observed polystyrene
nanoparticles of size of 220 nm within the epithelial cells of jejunum 1 hour after
administration of these particles by oral gavage in rats, and after 2-4 hours the
nanoparticles were observed in the interstices of the lamina propria and the
lymphatics of mucosa (32). The observation of uptake of nanoparticles by the
lining of the cells of the intestinal mucosa was also supported by the electron
microscopic autoradiographic investigation by Kreuter et.al. (33). This
intracellular uptake suggests an endocytic uptake mechanism, which was also
proposed by Jani et. al. (29) as a secondary pathway for intestinal uptake
polystyrene particle of diameter 100 nm.
M-Cells are classified as specialized epithelial cells which are generally
found on the follicle-associated epithelium overlying Peyer’s patches.
Microscopically, the epithelial overlying these patches contain a small number of
goblet cells, as a result, mucus secretion is reduced rendering M cell’s surface as
more conductive to antigen binding. For these reasons, M-cells may also be more
easily accessible for nanoparticles (34). This can be validated by the observation
by Jani et. al. (29) wherein they observed the uptake of polystyrol nanoparticles
exhibiting fluorescent and ranging from a size range of 100 nm and 1µm by the
Peyer’s patches following oral gavage to mice daily for 10 days. The
nanoparticles were found to be concentrated in the serosal side of the Peyer’s
patches and following a histological investigation revealed the translocation of
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particles of size 1 µm and smaller from the Peyer’s patches to the mesenteric
lymph nodes leading to the lymphatic system. In a comparison of radiolabeled
(125I) labeled particles of sizes 100 nm and 1 µm, smaller sized particles showed a
higher uptake, with smaller particle being observed in liver and spleen, with no
evidence for uptake of particles of sizes 3 µm and higher by the gut (35).
As illustrated above, evidence for all three pathways exists. However,
many researches have reported the simultaneous occurrence of more than one
pathway for the uptake of nanoparticles by the GI tract (28–30,32). For example,
Damgé et. al. (27) reported a preferential uptake of lipiodol-loaded nanoparticles
via intercellular spaces between the enterocytes in the jejunum 10-15 minutes
following oral administration to canine and rats. Wherein large quantities of
particles passed through the M-cells of the ileum and were found to be in the
intercellular spaces around the lymph nodes simultaneously. In addition to this,
Scherer et. al. (36), in their in vitro diffusion experiment, observed by using laser
confocal microscopy that fluorescence appeared in localized patches when
fluorescein isothiocyanide (FITC) labeled nanoparticles were applied onto either
porcine or rabbit small intestine, as compared to homogenous distribution over
this tissue when FITC or FITC labeled dextran solution was applied. In the same
study, if 14C-labelled poly(butyl cyanoacrylate) nanoparticles were placed into the
chamber facing the brush border side of the porcine intestinal tissue in a twochamber side-by-side diffusion cell, no radioactivity translocated to the acceptor
chamber within 4 hours, if the mounted tissue came from the upper part of the
small intestine. On the other hand, a significant amount of radioactivity was
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observed in the acceptor chamber, when lower part of small intestine that
possessed a considerable number of M-cells and Peyer’s patches was mounted.
Further evidence to prove the importance of Peyer`s patches for the intestinal
uptake of nanoparticles has been provided by Jani et. al. (26,29,37), who observed
that uptake of nanoparticles into the Peyer’s patches and passage via the
mesentery lymph supply, leading to general circulation, in rats, increased with
decrease in particle size. The surface properties of the nanoparticles may also
have some influence on the uptake mechanism. Jani et. al. (29) observed that
carboxylated polystyrene nanoparticles as compared to non-ionized polystyrene
particles of similar particle size were taken up to a considerably lower degree.
It appears, therefore, that the major uptake pathway is via the M-cells and
Peyer’s patches in the gut attributed to the reduced amount of mucus.
Additionally, particle size and surface properties of the nanoparticles play a
crucial role in intestinal uptake of orally administered nanoparticles. However, it
also suggests that major uptake pathway may be different in different regions of
the small intestine (35).
As illustrated above, no uncertainty exists that absorbed nanoparticles
appears in the blood stream. One such pathway of transportation is via lymphatic
uptake and entry into the general circulation via the thoracic duct (Figure 1) (35).
Another such pathway is the direct delivery of the nanoparticles from the
intestinal wall into the blood capillaries, which involves crossing of two types of
barrier upon their inter-epithelial or transcellular uptake (Figure 2) (28): the
basement membrane (38,39) and the wall of the capillaries (35). Additionally,
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occurrence of channels formed by fenestral diaphragms of variable sizes in the
epithelial cells based on their location and surrounding physiological conditions
(40), could permit nanoparticles to pass through the endothelium subsequently
reaching to the capillaries (28).
In terms of kinetics, Volkheimer (31) reported an interesting observation:
that the appearance of the particles in the blood does not represent a simple firstorder process (absence of single blood level maximum). But rather, 2-3 maxima:
first being very rapid (after few minutes), and a lag time of about 100 and 210
minutes between the second and third maxima respectively following oral
administration. These multiple maxima thus indicate the possibility of different
uptake mechanism as discussed earlier.
2.3. Brain targeting of surface modified nanoparticles
As discussed in previous section, that the BBB represents an
insurmountable barrier for the delivery of substantial number of drugs to the
brain. One of the possibilities to tackle this challenge is by using surface modified
nanoparticles for achieving drug delivery to the brain. Various drugs, such as
loperamide, tubocurarine, doxorubicin, dipeptide kytorphin (41) and hexapeptide
dalargin (6), were loaded on the surface modified nanoparticles and administered
via either intravenous injections or peroral administration. Amongst these drugs,
the most encouraging results were obtained with doxorubicin for the treatment of
brain tumors. Intravenous injection of polysorbate80-coated nanoparticles loaded
with doxorubicin (5 mg/kg) in rats achieved high brain levels of 6 µg/g of brain
tissue as compared to controls (including the solution of polysorbate 80
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containing doxorubicin along with uncoated nanoparticles) (41). The possible
mechanism of the doxorubicin transport across the BBB has been postulated to be
via endocytic uptake by the brain capillary endothelial cells followed either by
release of the drugs in these cells and diffusion into the brain or by transcytosis.
Additionally, the injected nanoparticles adsorb apolipoprotein E (apo E) or apo B
in the systemic circulation to facilitate the interaction with the low-density
lipoprotein receptor in the brain followed by endocytic uptake, representing the
uptake of naturally occurring lipoproteins. This hypothesis was well supported by
the achievement of antinociceptive effect using dalargin-loaded poly(butyl
cyanoacrylate) nanoparticles with surface adsorbed apo E or loperamide-loaded
albumin nanoparticles with apo E as a covalently attached homing device (41).
In one such study to demonstrate the uptake of dalargin loaded
biodegradable poly(butyl cyanoacrylate) nanoparticles as a result of overcoating
with surfactants such as polysorbate 80 and polyethylene glycol (PEG) 20000,
Das and Lin (6) reported a significant dose- and time- dependent pharmacological
effects in the CNS following oral administration into mice, whereas all controls,
did not achieve dalargin-induced analgesia. The results clearly indicates that the
drugs loaded on double-coated poly(butyl cyanoacrylate) indeed crossed the GI
barrier and after oral administration and were transported across the BBB (6).
Similar results were obtained by over coating of biodegradable nanoparticles
when administered orally (11). Additionally, these nanoparticles also retained
their targeting potential when coated with polysorbate 20, 40 and 60 contraries to
this, large number of other surfactants were not able to achieve delivery across the
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BBB (42). Give these in vivo observations demonstrating nanoparticle mediated
drug uptake by the BBB, important questions need to be addressed. These
includes: 1) mechanism of nanoparticle–mediated drug uptake by the BBB, 2)
influence of surface properties in targeting efficiency, 3) quantification of drug at
target site transported via this pathway to achieve significant pharmacological
effects with reduced toxicity to the healthy cells (7)
Two major possibilities were reported by Kreuter. J (7) to elucidate the
mechanism of nanoparticle-mediated uptake of drugs into the brain: 1)
endocytosis by the endothelial cells with subsequent release of the drugs within
these cells and delivery to brain, 2) transcytosis through the endothelial cell layer
(43). This mechanism has been demonstrated by in vitro studies of nanoparticles
over coated by polysorbate 80 into several primary endothelial cell lines including
mice (44), rat (45) as well as primary bovine (46,47) and human endothelial cells
(47). Additionally, in vitro studies also demonstrated the surface adsorption of
apolipoproteins E or A-I (apo E or apo A-I) of nanoparticles coated with
polysorbate 80 upon their incubation in blood plasma (48).
For this reason, in vivo experiments were performed (49), which
concluded that polysorbate 80 specifically mimics as an anchor for the
apolipoprotein which interact with low density lipoprotein (LDL) receptors on the
brain capillary endothelial cells (50–52). This hypothesis was then challenged by
Michaelis et. al. (53) and wherein pronounced antinociceptive effects was
achieved when human serum albumin nanoparticles covalently bound to apo-E
instead of cyanoacrylate nanoparticles with polysorbate 80 overcoat was used.
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Later, comparable results were obtained by Kreuter et. al. (54) by covalently
attaching apo A-I or apo B-100 to serum albumin nanoparticles. Apo A-I can
interact with the scavenger receptor class B type I (SR-BI) (55,56) whereas, apo E
and B with the LDL receptor. Therefore, interaction with these receptors,
followed by endocytosis and transcytosis across the brain capillary endothelial
cells appears to be the underlying mechanism for surfactant-coated nanoparticle
mediated drug delivery, or albumin nanoparticles with adsorbed or covalently
linked homing device such as the apolipoprotein A-I, B and E. The nanoparticle
thus would mimic lipoprotein particles and act as trojan horses for LDL receptors
(7).
2.4. Fabrication of nanoparticles
A major requirement for nanoparticulate mediated uptake of drugs to brain
is the biodegradable property of nanoparticles. Non-biodegradable nanoparticles
such as fullerenes, metal particles, and toxic systems such as quantum dots, or
potential risky needle-shaped delivery system such as carbon nanotubes, might
have hazardous effects like asbestos. Therefore, non-biodegradable nanoparticles
might not be useful for drug delivery (57).
For this reason, three major types of biodegradable nanoparticulate
materials like poly (alkyl cyanoacrylates) (PACAs) such as poly (butyl
cyanoacrylate), poly(lactic acid) or its copolymer poly(lactide-co-glycolide)
(PLGA), and human serum albumin have been the material of choice (57). Of
these material, poly (butyl cyanoacrylate) has comparatively faster
biodegradation, but it was not employed as polymers until the early 1980s (58).
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However, the corresponding monomers, alkyl cyanoacrylates, have been used
since 1966 for their excellent adhesive properties, resulting from the bonds of
high strength they are able to form with most polar substrates, including living
tissues and the skin (59). Therefore, these monomers have been extensively used
as tissue adhesives for skin wound closure (60–62), as embolic material for
endovascular surgery and as surgical glue (63). Many researches have also
reported the successful use of PACA as nanoparticulate carriers (64–67).
Moreover, the use of PACA as drug nanoparticulate carriers has gained increasing
interest in therapeutics, especially in case for cancer treatments (68). Today,
PACA nanoparticles are considered as one of the most promising polymeric
nanoparticulate carrier system and are already in clinical development for its
potential use in cancer therapy (12,69). They can be prepared by four major
methods, such as emulsion polymerization, polymerization in a continuous
aqueous phase, emulsion polymerization in a continuous organic phase, and
interfacial polymerization (70,71). Among which, emulsion polymerization has
been widely employed for fabrication of nanoparticles, and hence will be
reviewed in detail, while others will be shortly reviewed.
Emulsion polymerization is amongst the most popular approach used to
synthesize polymer colloids with matrix structure. The polymerization medium is
generally aqueous making the process less hazardous. The cyanoacrylate
monomers can be added in concentration between 0.05-7% (72). An anionic
polymerization mechanism has been proposed, which is initiated by bases present
in the aqueous polymerization medium. The cyanoacrylates are mainly initiated
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by the hydroxy (OH-) ions either resulting from the dissociation of water or in
some cases basic drugs. This hydroxyl ion induced polymerization is rapid and for
this reason the pH of the aqueous medium is kept below 3.5 and with some drugs
even below 1.0, to enable the formation of nanoparticles. Concomitantly, this
polymerization generates hydrogen (H+) ions, wherein the hydrogen ion
terminates the reaction. As a result of this termination, the molecular weights after
the polymerization is very low and has been observed to be inversely related to
change in pH (72,73). Due to low molecular weights, the nanoparticles are prone
to agglomeration. And for this reason, stabilizers (e.g., high molecular weights
dextran) are added to the system, which also significantly influences particle size
and molecular weights (74,75). However, the influence of pH on particle size is
somewhat different: particle size minimum exists around a pH of 2, whereas
polydispersity falls with increasing pH, until a plateau is reached at pH 2.5 and
above. Other factors contributing to the particle size of the nanoparticles includes
monomer concentration and the stirring speed. Wherein a slight particle size
minimum observed at monomer concentration of about 2% (74) and slight
increase in particle size with increasing stirring speed.
Emulsion polymerization in a continuous organic phase was one of the
first process employed to produce nanoparticles (76–78). PACA nanoparticles
were obtained by adding the cyanoacrylate monomer to continuous organic phase
due to its high solubility in organic solvent. Consequently, small percentage of
nanoparticles with a shell-like wall (nanocapsules) along with solid, monolithic
nanoparticles were obtained (79). The formation of PACA nanoparticles by
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employing interfacial polymerization in an aqueous surrounding phase was
introduced by Al Khouri Fallouh et.al. (80). Wherein the cyanoacrylate monomer
as well as the oil-soluble drug were dissolved in a mixture of oil and ethanol in
ratio of about 1:10 to 1:200. The organic solution containing the drug and the
monomer was then added slowly through a tube or needle into water or buffer
solution (pH 3-9) containing surfactant such as poloxamer 188 or 407 or
phospholipids, which resulted in the spontaneous formation of nanocapsules
consisting of an internal oil droplet surrounded by polymeric wall (81).
2.5. Fabrication of oral double-coated nanoparticles for brain delivery
In designing of oral drug delivery systems, the stability of the loaded drug
within the polymeric carrier matrix upon its contact with GI fluids plays a crucial
role. This consideration is especially important, if the loaded drugs is acid-labile
and if the polymeric carrier is biodegradable. One of the proposed strategies for
protecting biodegradable polymers and the entrapped labile drug from the effects
of the GI fluids can be obtained by application of polymeric coating such as
poly(ethylene) glycol (PEG) and the process referred as PEGylation (82–85).
In the event of any ‘foreign’ particulate reaching the circulation following
oral absorption, there lies an obvious problem of clearance by the reticuloendocytic system (RES). So, for any nanoparticle increase of circulation half-life
is an essential for it to stay in the blood for an extended period while retaining its
targeting potential. Such a long circulating effect can be achieved by employing
‘stealth’ or sterically stabilized properties by PEG coat over nanoparticles
(86,87). Generally, the assumed mechanism is the formation of, hydrophilic
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coating, to avoid opsonization by the plasma proteins and due to the dynamic
structure of PEG, the immune system experiences difficulties in modelling an
antibody around it (88). It is generally agreed, that only if a polymer chain
possesses both hydrophilicity and flexibility properties (to enable a high number
of possible chain conformations) can serve as an effective protecting coat for
particles against opsonization (89). Additionally, it has been proposed that both
reduction of adsorption of opsonin and selective adsorption of certain components
of plasma (dyopsosins) prevent the recognition as well as uptake of nanoparticles
by the macrophages. Researches on the usage of PEG over coat for ‘stealth’
properties, now agree that PEG is termed as a ‘dysphonic’ polymer which by
virtue of its selectivity in adsorption of two serum components (one with
molecular weight below 30,000 Dalton (Da) and the other with a molecular
weight higher than 100,000 Da) leads in a dysphonic action (90).
Thus, for nanoparticles that could survive oral administration and still
retain targeting properties to brain, a ‘double coat’ of PEG and polysorbate 80 can
be hypothesized. PEG as discussed above is well known for its protective action
in the GI environment along with its ability to enhance the circulation half-life of
nanoparticles. On the other hand, requirement of polysorbate 80 coating for apo E
mediated brain targeting of nanoparticles has been discussed in earlier sections. In
addition to the use of PEG to impart stealth properties, polysorbate 80 over coat
might also be useful in GI uptake of particulate by fluidizing action on the mucus
barrier, one of the factors that can be exploited in attempts to improve GI uptake
of the particulates (91,92).
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If nanoparticles are coated with an appropriate surfactant, then the extent
of particulate aggregation or entrapment in mucus can be reduced and uptake can
be enhanced (93). Therefore, in order to facilitate the uptake of nanoparticles by
the GI tract and subsequent delivery to brain via oral route, a ‘double-coating’ of
polymeric nanoparticles with high molecular weight PEG and polysorbate 80 has
been hypothesized. However, its success would depend on the stability of such
double coat in the biological systems. It is also to be appreciated that the choice of
PEG and polysorbate 80 as coating agents is dictated by number of physiological
factors, which can impart targeting and protective properties to nanoparticles.
2.6. Characterization of nanoparticles
2.6.1. Physicochemical characterization
Several physiochemical methods (Table 1) exists for the characterization
of nanoparticles. Among which particle size plays a crucial role and is most
eminent feature of nanoparticles. However, other parameters, such as density,
molecular weight, and crystallinity, largely influences the drug release and
degradation. Whereas surface properties, such as the surface charge,
hydrophilicity and hydrophobicity, significantly influence the interaction of these
particles with the biological environment and the resulting bio-distribution.
One of the fastest and routinely applied method for size measurements are
dynamic light scattering or photon correlation spectroscopy (94). Photon
correlation spectroscopy determines the hydrodynamic diameter of the
nanoparticles via Brownian motion. Therefore, the particle size analysis
measurements are influenced by the interaction of these particles with the
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surrounding medium. Consequently, the exact viscosity of the medium should be
known. Another method of size determination employs microscopic evaluation
and scanning electron microscopes (SEM) as well as transmission electron
microscope (TEM) are frequently used for this purpose. In addition to size
determination, SEM and TEM are used for analysis of morphological properties
of the particles (for example: porosity of the particles).
The molecular weights of polymeric nanoparticles are mainly determined
by dissolution of the particles in a suitable solvent followed by gel permeation
chromatography. However, this method is limited in its applicability due to the
lack of availability of polymer standards required to validate the results obtained
(95–97), (72).
Information about crystalline structure of nanoparticle may be obtained by
x-ray diffraction (94), differential scanning calorimetry (DSC), differential
thermal analysis (DTA), thermal gravimetric analysis (TGA), thermal mechanical
analysis (TMA) and thermal optical analysis (TOA) (98,99). These methods can
be quite useful in cases where small drug molecules are entrapped in the polymer
network in the form of an amorphous solid solution (100).
Hydrophobicity of the nanoparticles surface seems to have a much larger
influence on bio-distribution after intravenous injection. Water contact angle
measurements (101) and hydrophobic interaction chromatography (102) are two
major methods for the determination of hydrophobicity, since contact angle
measurements can be performed on the flat surfaces, and not on hydrated
nanoparticles in their dispersion media. As a result, hydrophobic interaction
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chromatography seems to be an efficient, although labor intensive method
(102,103).
2.6.2. Degradation pathway of polymeric nanoparticles
PACA are biodegradable polymers for which complete excretion of the
polymer material will occur if the nanoparticles were designed using lowmolecular weight polymers. The degradation of poly(alkyl cyanoacrylate) is
studied extensively, and two major degradation pathways has been described in
the literature. Firstly, degradation of polymer by erosion of the polymeric
backbone under formation of formaldehyde (104–106). Secondly, lysis of the
ester bond leading to the formation of soluble polymer acid in vivo (107).
Degradation product by this pathway results in the formation of an alkyl alcohol
and poly(cyanoacrylic acid), which are soluble in water and readily eliminated via
kidney filtration. This degradation has been shown to be catalyzed by esterases
from serum, lysosomes and pancreatic juice (108). According to this mechanism,
nanoparticles are usually degraded within a couple of hours depending on the
alkyl side chain length of the PACA forming the nanoparticles (109).
2.6.3. Drug release
Nanoparticle exhibit their special drug delivery effects (110) in most cases
by direct interaction with biological environment. Subsequently, the drug release
may occur by desorption of surface-bound drug, diffusion through polymeric
matrix, nanoparticle matrix erosion, or a combined erosion and diffusion
processes.

18

The release mechanism (matrix- type device), diffusion coefficient,
biodegradation rate of the polymeric backbone are the three main factors
controlling the drug release rate from the polymeric nanoparticles (111).
Additionally, release of the drug is also greatly influenced by the biological
environment, which is more pronounced as compared to conventional dosage
forms (e.g., tablets and capsules) as nanoparticles may be coated by plasma
proteins resulting in imparting an additional diffusional barrier leading to a
retardation in drug release. In addition, nanoparticles may have enhanced
interaction with biological or artificial membrane, leading to enhanced delivery of
drugs through these membranes in comparison to a simple solution (110).
An important point to consider is the quantification of the drug release
form these nanoparticles is technically difficult to achieve. This can be attributed
to the inability of the rapid and effective separation of the nanoparticle from the
dissolved or released drug in the surrounding medium owing to very small size of
the dosage form. At least five different methods for determination of in vitro drug
release, such as side-by-side diffusion cells with artificial or biological membrane
(110,112), dialysis bag diffusion (79,113,114), reverse dialysis sac (115),
ultracentrifugation (by analyzing the supernatant at pre-determined time points)
(116,117), ultrafiltration (79) have been reported.
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3. Research objectives and specific aims
There are three principle objectives of this research study. The first
objective is to fabricate double-coated doxorubicin-loaded poly(butyl
cyanoacrylate) nanoparticles of less than 300 nm to facilitate lymphatic uptake
and thereby by-pass the first-pass metabolism. The second major objective is to
evaluate their brain targeting potential after oral administration in rats. The third
major objective is to evaluate the potential of these double-coated doxorubicin
loaded nanoparticles in reversing the multidrug resistance
Specific aims include:
1. To fabricate double-coated doxorubicin-loaded biodegradable polymeric
nanoparticles composed of poly(butyl cyanoacrylate) with double-coats with
Tween 80 and PEG 20000 at various concentration level.
2. To characterize the fabricated nanoparticles based on their particle size, zetapotential, entrapment efficiency, drug leakage in various simulated mediums
(i.e., intestinal fluid and serum).
3. To evaluate the brain distribution of double-coated doxorubicin loaded
poly(butyl cyanoacrylate) nanoparticles after oral administration in Sprague
Dawley rats and based on pharmacokinetic study evaluate the role of
lymphatics in the oral absorption of double-coated doxorubicin loaded
poly(butyl cyanoacrylate) nanoparticles.
4. To investigate the potential of the fabricated double-coated doxorubicin
nanoparticles in the reversal of multi-drug resistance by cell uptake study or
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MTT assays using cell lines characterized for overexpression of P-gp and
BCRP transporters.
4. Materials and methods
4.1. Materials
The monomer n-2-butyl cyanoacrylate was purchased from Glustitch Inc
(Delta, Canada). Doxorubicin hydrochloride (henceforth referred as doxorubicin)
was purchased from BOCSCI Inc. (Shirley, New York). Dextran 70, sodium
chloride, pepsin, monobasic potassium phosphate, pancreatin, sodium
taurocholate, polyethylene glycol (PEG) 20000, 1% penicillin/streptomycin
solution, Whatman® microfiber pre-filters (2.5, 0.6 and 0.3 µm), TritonX-100,
sucrose, sodium azide, dynasore, and ammonium chloride were purchased from
VWR International (Radnor, PA). 1X Dulbecco’s phosphate buffered saline
(DPBS) and bovine serum (henceforth referred as serum) were purchased from
HyCloneTM (Logan, UT). Super Refined™ polysorbate 80 (Tween 80) was a
generous gift from Croda (Edison, NJ). The mouse brain endothelial (bEnd.3)
cells, 0.25% trypsin, and Dulbecco’s modified eagle medium (DMEM) (30-2002)
were obtained from American Type Culture Collection (Manassas, VA). The
human colon cancer cell line SW620 and its doxorubicin-selected P-gpoverexpressing SW620/Ad300 cells (henceforth referred to as AD300), the
NSCLC cell line NCI-H460 and its mitoxantrone-selected BCRP-overexpressing
NCI-H460/MX20 cells (henceforth referred to as AD300), were used for P-gp and
BCRP reversal study, respectively. Fetal bovine serum (non-heat activated) was
obtained from Atlanta Biologicals (Flowery Branch, GA). All reagents were of
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analytical grade and were used as received. Finally, previously published
literatures were used for preparation of release medium (pH 4.8) (118), and fasted
state simulated intestinal fluid (FaSSIF) (119).
4.2. Analysis of doxorubicin
4.2.1. UV-Vis spectroscopy method
The doxorubicin content in samples obtained from in vitro performance
studies was determined using UV-Vis Spectrophotometer (DU 700 series,
Beckman Coulter Inc., Brea, CA). At a preset wavelength of 480 nm, a peak,
characteristic of doxorubicin, has been reported (120). Serial dilutions of stock
doxorubicin solution (1000 µg/ml) were made to obtain concentrations ranging
from 0.1 to 50 µg/ml. Linear regression analysis was performed between the
absorbance and the concentration of doxorubicin to establish the calibration curve
using SigmaPlot 12.5 (Systat Software Inc., San Jose, CA).
4.2.2. Fluorescence spectroscopy method (plate-reader method)
The doxorubicin content from in vitro cell culture and in vivo studies was
determined using SpectraMax M5e (Molecular Devices, Sunnyvale, CA) at
λex=480 nm, λem=560 nm (121). For in vitro cell culture studies, serial dilutions of
stock doxorubicin solution were made to obtain various concentrations (0.033 to
3.33 µg/ml). Linear regression analysis was performed to establish the calibration
curve using SigmaPlot 12.5.
For in vivo samples, rat serum and tissue homogenates were spiked with
standard doxorubicin solution to obtain final concentrations (0.001 to 200 µg/ml).
Serum samples were then processed as described in the literature (122). Tissue
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homogenates were subjected to an additional lysis step by 1% TritonX-100. The
lysates were then extracted for determination of doxorubicin like serum samples.
Serum and tissue homogenates samples were analyzed by fluorescence
spectroscopy method and data was processed as described above.
4.2.3. Fluorescent microscopy method
The intracellular accumulation of doxorubicin was studied by using
fluorescence microscopy reported in the literature (123). SW620 cells were
chosen for their ability to take up doxorubicin readily. The images of the SW620
cells after treatment (i.e., incubation with doxorubicin in solution for a
predetermined period) along with the control (i.e., untreated cells) were collected
using EVOS® FL Auto Imaging System (Model AMFAD1000) (Thermo Fisher
Scientific, Fair Lawn, NJ). In order to take the images, the cells were visualized at
a total magnification of 1200× (40× objective with an internal magnification of
30×) using two different modes (i.e., phase contrast and fluorescence). Phase
contrast was used to locate a region of cells free from any cellular debris and/or
any overlapping cells. Fluorescence was used to determine doxorubicin
accumulation within the cells, which was achieved by selecting the RFP filter
(built-in the instrument) at a preset wavelength (excitation: 552 nm; emission: 585
nm). For both phase contrast as well as fluorescence, images of cells were
acquired using a monochrome camera also built-in the instrument.
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4.3. Fabrication of double-coated doxorubicin-loaded poly(butyl
cyanoacrylate) nanoparticles delivery systems (PBCA-NPDS)
The fabrication process of these formulations is illustrated in Figure 3
representing core (Figure 3A), and single- (Figure 3B) and double-coated
formulations (Figure 3C).
4.3.1. Doxorubicin-loaded PBCA-NPDS
The doxorubicin-loaded PBCA-NPDS were prepared by an anionic
polymerization method as reported, with modifications (124). Briefly, dextran 70
(1.5% w/w) was added to 0.001 N HCl solution in Nanopure® water (pH 3.00)
under constant magnetic stirring at low speed (500-800 rpm) with a Pyrex®
Spinbar® (VWR International, Radnor, PA). Once dextran 70 was completely
solubilized, butyl cyanoacrylate monomer solution (1% v/v) was added dropwise.
After 40 minutes of polymerization, doxorubicin (0.4% w/v) was then added.
Following 4 hours of polymerization, the dark red nanoparticle suspension was
neutralized with sodium hydroxide (0.1 N) and further stirred for an additional 12
hours to ensure complete neutralization. The nanoparticle suspension obtained
was then subjected to sequential filtration step using 1.2 µm, and 0.7 µm filters
with a vacuum filtration assembly. The filtered suspension was further subjected
to ultracentrifugation for two cycles (10 minutes each at 40000 rpm and 4-6°C)
using Optima XE ultracentrifuge, rotor Type 70 Ti (Beckman Coulter,
Indianapolis, IN). After each centrifugation step, the supernatant was removed,
and the nanoparticles were resuspended in the same amount of Nanopure® water
using brief sonication. Finally, the pelleted nanoparticles were immediately frozen
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using a freezing mixture of dry ice and alcohol. The frozen nanoparticles were
then immediately lyophilized using a Freezone 4.5 lyophilizer (Labconco, Kansas
City, MO). Lyophilization was carried out at -51°C and at a pressure of 0.018
mbar in the presence of 4% trehalose as a cryoprotectant overnight and then
stored at 2-8°C until further use.
When adding the doxorubicin during the polymerization, there remains an
obvious challenge of any undesirable chemical interaction between the
doxorubicin and nanoparticle backbone. This challenge intensifies, if the drug has
a reactive functional group (i.e., amine in doxorubicin). And, the polymer (poly
butyl cyanoacrylate group) has an ester group. Ester may covalently react with
amine to form amides. However, such reaction require microwave irradiation
(125), activated acid derivatives (126), or a catalyst (127). Since none of these
procedures were used in this study, no interaction between doxorubicin and the
monomer (butyl cyanoacrylate) has been hypothesized. To test this hypothesis,
the lyophilized doxorubicin-loaded PBCA-NPDS were analyzed by 1H nuclear
magenetic resonance (NMR) spectroscopy. This method is routinely used for
structural characterization and verification of chemical compounds based on the
bonding characteristics of the hydrogen atom. Briefly, samples were obtained by
dissolving the doxorubicin-loaded nanoparticles and free doxorubicin (control),
respectively, in deuterated-dimethyl sulfoxide (DMSO-d6). The solutions were
then filled in NMR tubes and were analyzed using NMR instrument (Bruker,
Billerica, MA). Samples were locked using an auto-shim mode, and spectrum
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acquisition was performed using TopSpin mode and number of scans were fixed
to 16 (default settings).
It should be noted that these doxorubicin-loaded PBCA-NPDS were
sequentially coated with either Tween 80 or PEG 20000 (single-coated) and with
Tween 80 and PEG 20000 (double-coated) as described below.
4.3.2. Single-coating of doxorubicin-loaded PBCA-NPDS
About half of the doxorubicin-loaded PBCA-NPDS obtained from the
above step were coated with varying concentrations of up to 2% of Tween 80
relative to the total suspension of nanoparticles in DPBS. Depending upon the
amount of coating of Tween 80 used for formulation, T1 (1% Tween 80) or T2
(2% Tween 80) was assigned as part of the formulation code. For each
formulation, the required quantities of Tween 80 were added to the above
suspension. This suspension was then kept in a water-shaker bath, maintained at
25° ± 0.5° C and 100-120 cycles per minute for 90 minutes.
About a quarter of doxorubicin-loaded PBCA-NPDS obtained were coated
with 1% of PEG 20000 in the same way as described above. Since these
formulations did not contain Tween 80, they were categorized under single-coated
formulation.
4.3.3. Double-coating of doxorubicin-loaded PBCA-NPDS
About half of Tween 80 overcoated doxorubicin-loaded PBCA-NPDS
obtained from the above step was further overcoated with varying concentrations
of up to 2% of PEG 20000 relative to the total suspension of nanoparticles in
DPBS. Depending upon the amount of coating of PEG 20000 used for
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formulation, P1 (1% PEG 20000) or P2 (2% PEG 20000) was assigned as part of
the formulation code. For each formulation, the required quantities of PEG 20000
was added to the above suspension. This suspension was then kept in a watershaker bath, maintained at 25° ± 0.5° C and 100-120 cycles per minute for 90
minutes. Thereafter, the suspension of these double-coated doxorubicin-loaded
PBCA-NPDS was further stirred for overnight to ensure complete equilibration of
coating material (Tween 80 and PEG 20000) with doxorubicin-loaded PBCANPDS.
4.4. In vitro evaluation of double-coated doxorubicin-loaded PBCA-NPDS
All doxorubicin-loaded PBCA-NPDS (core, single- and double-coated)
formulations were evaluated and characterized by their particle size, zeta
potential, entrapment efficiency, drug release and drug leakage.
4.4.1. Particle size and zeta potential
All formulations (5 mg) were suspended in 1 ml DPBS by brief
sonication. This homogenous suspension was then transferred to a folded
capillary cell (DTS1070) (Malvern Panalytical Inc. Westborough, MA). After a
brief equilibration period inside the sample chamber, the mean hydrodynamic
particle size (nm), the polydispersity of size distribution (PdI) and zeta potential
were measured. For particle size analysis, dynamic light scattering along with
Non-Invasive Back Scatter Technology built-in the Zetasizer Nano ZS (Malvern
Panalytical Inc. Westborough, MA) was used. Zeta potential was measured using
laser doppler micro-electrophoresis also built-in the Zetasizer Nano ZS.
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4.4.2. Entrapment efficiency
The amount of drug entrapped was determined by completely dissolving
the lyophilized doxorubicin-loaded PBCA-NPDS (5.50 mg) in 5 ml
methanol:acetonitrile (50:50) solution. The resulting solution was centrifuged at
13300 rpm for 10 minutes at 4° ± 0.5°C to pelletize any undissolved materials.
The clear supernatant was analyzed for doxorubicin content by the UV-Vis
spectroscopy method described previously. The entrapment efficiency of
doxorubicin was then calculated as a ratio of the assayed doxorubicin in
lyophilized doxorubicin-loaded PBCA-NPDS to the total doxorubicin (i.e., 400
mg) used in the fabrication as reported in the literature and shown below (128)
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =

𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑓𝑒𝑑 𝑖𝑛𝑖𝑡𝑎𝑙𝑙𝑦

× 100

Equation 1

4.4.3. In vitro drug release kinetics
Among various methods to study the drug release from various nanoformulations (liposomes, nanoparticles, etc.), usage of the dialysis membrane bag
has been widely discussed in literatures (129–134). However, the selection criteria
of a dialysis membrane bag over another is seldom reported (134,135). Therefore,
the evaluation of various types of dialysis membrane bags and the effect of
doxorubicin concentration on its diffusion rate through dialysis membrane bags
were performed, prior to in vitro drug release study.
4.4.3.1. Screening of dialysis membrane bags
The selective diffusion of drugs (based on molecular weight) across a
semi-permeable dialysis membrane bags is the main principle to separate the drug
released from nano-formulations and subsequently allow the sampling of drug
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released. Four different Float-A-Lyzer G2 dialysis membrane bags (Repligen,
Walthman, MA) of different MWCOs (i.e., 50, 100, 300, and 1000 KDa) were
evaluated. Briefly, doxorubicin standard solution (1 mg/ml) was prepared by
dissolving the desired amount of doxorubicin in the release medium and 1 ml of
this standard solution was transferred to inside each of the hydrated dialysis
membrane bags as per the user’s manual provided by the manufacturer. These
sealed dialysis membrane bags were then placed into 50 ml polypropylene tubes
having 20 ml release medium at 37° ± 0.5°C and 100-120 rpm using a watershaker bath. At pre-determined time intervals (i.e., 1, 2, 3, 4, 5, and 6 hours),
aliquots (1 ml each) were withdrawn from the outside of the dialysis membrane
bags and replaced by an equal volume of release medium. The aliquots were
analyzed for doxorubicin content using the UV-Vis spectroscopy method
described previously.
4.4.3.2. In vitro release study
All lyophilized doxorubicin-loaded PBCA-NPDS formulations (equivalent
to 5.60 mg of doxorubicin) were suspended in 5 ml of release medium,
respectively. The resulting nanoparticle suspension were transferred to inside of
the hydrated dialysis membrane bags. After seating the bags, they were then
placed into flat bottom glass tubes (130 mm × 40 mm) having 100 ml release
medium at 37° ± 0.5°C and 100-120 rpm. At pre-determined time intervals (i.e.,
1, 2, 3, 6, 9, 12, 24, 36, 48, 60, and 72 hours), aliquots (1 ml each) were
withdrawn from the receiver and replaced by an equal volume of release medium.
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The released doxorubicin in aliquots was determined by the UV-Vis spectroscopy
method described previously.
4.4.4. Drug-leakage in various simulated mediums
To maximize the payload of doxorubicin at the target site following oral
administration, drug leakage from dosage forms in the gastrointestinal tract and
serum was evaluated.
4.4.4.1. Fasted state simulated intestinal fluids (FaSSIF)
Lyophilized doxorubicin-loaded PBCA-NPDS formulations (5.60 mg)
were dispersed in 1 ml FaSSIF. The dispersions were then transferred into dialysis
membrane bags (MWCOs: 1000 KDa) and dialysis was performed in tubes
containing 30 ml FaSSIF at 37°C 100-120 rpm for 12 hours. Thereafter, an
aliquot was withdrawn from the receiver and analyzed for doxorubicin content by
the UV-Vis spectroscopy method described previously.
4.4.4.2. Serum
The leakage study in serum was performed by dispersing lyophilized
doxorubicin-loaded PBCA-NPDS formulations (5 mg) in 10 ml of serum at 37°C
and 100-120 rpm for 3 hours. After this time, aliquots were subjected to protein
precipitation and drug extraction using ice-cold methanol. The extracts were
analyzed for doxorubicin content by the UV-Vis spectroscopy method described
previously.
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4.5. In vitro model to elucidate the brain uptake mechanism
4.5.1. Uptake mechanism elucidation using specific inhibitors as a
pretreatment
For uptake mechanism elucidation, we hypothesize that pretreating the
bEnd.3 cells with inhibitors of transporters responsible for up taking nanoparticles
would impact the uptake of doxorubicin within the same cells upon further
incubation with formulation T2P2 or free doxorubicin in solution (control). Based
on this hypothesis, bEnd.3 cells were pretreated with the growth media (no
pretreatment) as a control group. In addition, cells were pretreated with an
endocytosis inhibitor sodium azide (0.1%w/v) (136), and by incubation at 4°C. To
evaluate the role of clathrin-mediated endocytosis, cells were pretreated with
sucrose (0.45 M) (137). Since bEnd.3 cells also expresses LDL receptors (138),
cells were pretreated with LDL receptor inhibitor dynasore (5 µM) (139).
Furthermore, to evaluate the involvement of the endosomal/lysosomal
compartments in the trafficking of nanoparticles pretreatment with
lysosomotropic agent ammonium chloride (140) was performed. After initial
pretreatment (i.e., 1 hours), the cells were washed with cold DPBS. Thereafter,
pretreated cells were further incubated with formulation T2P2 or free doxorubicin
in solution (control) for additional 3 hours, followed by cell lysis by mixture of
0.1 ml of equimolar mixture of 1% TritonX-100 and 0.2 N sodium hydroxide, and
0.4 ml of methanol and doxorubicin content determination by the fluorescence
spectroscopy method described previously. Furthermore, any potential
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cytotoxicity of inhibitors on bEnd.3 cells was investigated by modified MTT
colorimetric assay (141), by incubating the cells for 4 hours with various
inhibitors at concentration levels described above.
4.5.2. Permeability screening study
Permeability screening study was performed on bEnd.3 cells monolayer
by seeding 4 × 105 cells per Transwell® permeable support inserts (pore diameter:
0.4 μm). The integrity of the cell monolayer was checked at the beginning and the
end of experiments by measuring the transepithelial electrical resistance (TEER)
using EVOM2 (World Precision Instrument, Sarasota, FL). Additionally, leakage
of Lucifer yellow (paracellular marker) across the monolayer was determined at
the end of experiment. Permeability study were conducted by incubating
formulation T2P2 or free doxorubicin solution (control) on the apical or
basolateral side, at 37°C and 5% CO2 for 2 hours. After this, the concentration of
doxorubicin in the receptor compartment (i.e., basolateral or apical) was
quantified by fluorescence spectrophotometric method described previously, and
the apparent permeability coefficients (Papp) were calculated as shown in Equation
2 (142).
𝑃𝑎𝑝𝑝 (𝑐𝑚. 𝑠 −1 ) =

𝑄
𝐴 ×𝐶 × 𝑡

Equation 2

Where, Q represents the total amount of permeated doxorubicin (μg), A is the
surface area of the filter (cm2), C is the initial doxorubicin concentration in the
donor compartment (μg.ml-1), and t is the incubation time (s). For all permeability
experiments, bEnd.3 cells were used prior to passage 35 (143).
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4.6. In vivo performance of double-coated doxorubicin loaded PBCA-NPDS
The in vivo performance studies were evaluated using Sprague-Dawley
(SD) rats (225-250 g) (Taconic Biosciences, Germantown, NY). All experiments
were conducted as per approved protocol by Institutional Animal Care and Use
Committee. Rats were divided into 4 groups with 4 rats in each group. Groups 1,
2, and 3 received formulation T2P2 at a dose equivalent to 27, 50, and 70 mg/kg
of doxorubicin, respectively. Group 4 received free doxorubicin in solution at a
dose of 70 mg/kg (control group). Two (2) routes of administration [i.e.,
intravenous- group 1, oral- group 2-4] were evaluated.
4.6.1. Biodistribution study
For biodistribution study, two (2) rats from each group (described above)
were euthanized at 1 and 2 hours for group 1, and, 1 and 3 hours for groups 2-4 by
carbon dioxide asphyxiation, and brain, and liver tissues were collected. Isolated
tissues were immediately wiped to remove blood, subsequently, they were
weighed and placed on ice immediately. For analysis, tissues were homogenized
at 5000 rpm using VirTis TEMPEST I.Q2 homogenizer (Tempest Inc., Cleveland,
OH) and doxorubicin was extracted and determined as described previously.
4.6.2. Pharmacokinetic study
Following the dose administration (i.e., intravenous via the saphenous vein
and oral gavage), blood samples were collected via tail clipping at predetermined
time intervals for up to 2 hours and 3 hours for group-1 and group 2-4,
respectively. Blood samples were collected in serum separating tubes
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(MiniCollect® Tube) (Greiner Bio-One, Kremsmünster, Austria). Serum was
separated, and doxorubicin concentration was determined as described previously.
4.7. In vitro cell culture studies
4.7.1. Intracellular accumulation study of various in doxorubicin-loaded
PBCA-NPDS in SW620, AD300 and bEnd.3 cell lines
SW620 and AD300 were seeded in their respective growth medium in 24well plate and cells were allowed to grow overnight at 37°C, 5% CO2. On the day
of the experiment, cells were washed with DPBS (pH 7.4) three times.
Subsequently, the cells were treated with 5 µM free doxorubicin in solution, all
nanoparticles formulations (equivalent to 5 µM doxorubicin), and blank ( growth
mediums). The treated cells were then incubated for 2 hours at 37°C, 5% CO2.
Following the incubation period, the treatment (free drug, nanoparticles
formulations, or growth medium) was aspirated. The cells were then gently
washed with DPBS three times. And, then immediately examined the cells using
the fluorescence microscopy method described previously. For this study, singlecoated formulations, free doxorubicin, and growth medium served as controls.
Since it is difficult to estimate the amount of up taken doxorubicin from
microscopic images. An empirical parameter [i.e., corrected total cell
fluorescence (CTCF)], expressed as fluorescence intensity, was chosen for
indirect quantification of doxorubicin within the cell (144). CTCF was obtained
after subtracting the intensity of the blank cells (background), from cells
exhibiting fluorescence. This was performed using ImageJ® software (National
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Institutes of Health, Bethesda, MD). Higher fluorescence intensity was used as a
surrogate for higher intracellular accumulation of doxorubicin.
4.7.2. Cytotoxicity determination of various doxorubicin-loaded PBCANPDS to evaluate their P-gp and BCRP efflux transporter inhibition
potential
The modified paraformaldehyde, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide (MTT) colorimetric assay was used to detect the
sensitivity of cells to doxorubicin as well as double-coated doxorubicin-loaded
PBCA-NPDS in vitro (141). Briefly, cells were loaded in 180 µl of complete
growth medium in 96-well plates in triplicate at cell density of 5000-6000
cells/well. After incubation at 37°C, 5% CO2 for 24 h, cells were treated with
different concentrations of free doxorubicin or double-coated doxorubicin-loaded
PBCA-NPDS (20 µl/well). After 72 h incubation at 37°C, 5% CO2, 20 µl of MTT
solution (4 mg/ml) was added to each well. The plates were further incubated at
37°C, 5% CO2 for 4 h, enabling viable cells to change the yellow-colored MTT
into dark-blue formazan crystals. Subsequently, the MTT/medium was carefully
aspirated from each well without disturbing the cell, and 100 µl of DMSO was
added into each well. Plates were placed on shaking table to ensure thorough
mixing of formazan into DMSO. Finally, the absorbance was determined at 570
nm using microplate reader (ThermoFisher Scientific, Waltham, MA) and data
acquisition was performed by SkanIt™ software (ThermoFisher Scientific).
4.8. Data analysis
4.8.1. Pharmacokinetic data analysis

35

To overcome the limitation of sparse data in animal studies, pooled
analysis of serum doxorubicin concentration-time curves obtained were analyzed
using compartmental analysis using WinNonlin® (Pharsight, Cary, NC). The
parameter estimation during the model fitting analysis was performed using a
Gauss-Newton algorithm with Levenberg-Hartley modification. The Akaike
information criteria (AIC), lack of systemic deviations in the residuals was
considered as goodness of fit criteria (145). Equation 3 and 4 was employed for
simultaneous model fitting of serum concentration-time profiles obtained after
intravenous and oral administration, respectively.
𝐶𝑝 = 𝐴𝑒 −𝛼𝑡 + 𝐵𝑒 −𝛽𝑡

Equation 3

where, Cp is the plasma concentration of doxorubicin at time t, A is y-intercept of
first-order rate process of distributive phase and B is y-intercept of first order
process of elimination phase, α is hybrid rate constant for distributive phase and β
is hybrid rate constant for elimination phase.
𝐶𝑝 = 𝐴𝑒 −𝛼(𝑡−𝑡𝑙𝑎𝑔) + 𝐵𝑒 −𝛽(𝑡−𝑡𝑙𝑎𝑔 ) + 𝐶𝑒 −𝑘𝑎(𝑡−𝑡𝑙𝑎𝑔 )

Equation 4

Where, A is y-intercept of first-order rate process of the absorption phase and B is
y-intercept of first order process of distributive phase C is y-intercept of firstorder process of elimination phase, ka is first-order absorption rate constant, and
tlag is the lag time associated with drug absorption. After obtaining the values of
primary parameters (i.e., A, α, B, and β) from model fitting analysis (Equation 3),
the values of secondary parameters such as volume of distribution (V), clearance
(CL) were further calculated using the WinNonlin. Thereafter, the drug and
animal related parameters [i.e., V, and CL] were treated as fixed parameter during
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the simultaneous model fitting analysis. This assumed that clearance remains
constant between two study occasions (i.e., intravenous, and oral administration).
Thereafter, the dosage form related parameters (i.e., ka, and tlag) were estimated
by model fitting.
4.8.2. Statistical analysis
All the acquired data were expressed as mean ± standard deviation (SD),
and analyzed with SigmaStat 3.5 (Systat Software Inc., San Jose, CA).
Differences between multiple groups were evaluated by one-way analysis of
variance (ANOVA) followed by Holm-Sidak post-hoc analysis to determine the
groups, which showed signiﬁcant difference. Differences between two groups
were evaluated by the student’s t-test. In each case, a p-value less than 0.05 was
considered as a representation of signiﬁcant difference.
5. Results and discussion
5.1. Analytical methodology
The absorbance (Figure 4) and fluorescence intensity (Figure 5) were
found to increase linearly with the concentration of doxorubicin within the
measured concentration range with a regression coefficient (r2) value of more than
0.995. These results indicated that both the UV-Vis and fluorescence
spectroscopy method, adopted for the detection and quantification of doxorubicin,
are reliable methods. Furthermore, an ease of visualization of the drug by
fluorescent microscopy method (Figure 6) also indicates it suitability for its usage
in determination of doxorubicin.
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5.2. Fabrication and characterization of double-coated doxorubicin loaded
PBCA-NPDS
For convenience in terminology, all formulations were coded based on the
level of Tween 80 and PEG 20000 coating. For example, formulation T2P2
(representing 2% Tween 80 and 2% PEG 20000). The particle size, polydispersity
index (PdI), zeta potential and entrapment efficiency of various non-coated and
coated doxorubicin-loaded PBCA-NPDS formulations in comparison with blank
PBCA-NPDS nanoparticles (placebo) are summarized in Table 2. And, 1H NMR
spectrum to evaluate the interaction of the polymeric core with doxorubicin is
shown in Figure 7.
As expected, the mean particle size of doxorubicin-loaded PBCA-NPDS
(formulation T0P0) increased due to doxorubicin loading as compared to that of
blank PBCA-NPDS (154.5 nm vs. 109.4 nm). This increase in size could be
attributed to interference in the surface deposition of dextran 70 (surfactant)
chains caused by the presence of the doxorubicin during the polymerization step.
As a result, their adsorption on PBCA-NPDS may have reduced, leading to an
increase in the particle size (146). Further coating of doxorubicin-loaded PBCANPDS with Tween 80 and PEG 20000 at 1%, respectively, the mean particle size
of single-coated doxorubicin-loaded PBCA-NPDS increased to 182.6 nm
(formulation T0P1) or remained similar size at 154.4 nm (formulation T1P0).
This could be attributed to the high MW of PEGs (MW > 5000 Da) resulted in the
formation of a layer-wise polymeric network on the surface of PBCA-NPDS
(147). Furthermore, with a double coating with Tween 80 at 1% and PEG 20000
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at either 1% or 2%, mean particle size of the double-coated formulations
increased from 154.4 nm (formulation T1P0) to 203.6 nm (formulation T1P1) and
256.9 nm (formulation T1P2). In addition, with double coating with Tween 80 at
either 1% or 2% and PEG 20000 at 1%, mean particle size of the double-coated
formulations increased from 182.6 nm (formulation T0P1) to 203.6 nm
(formulation T1P1) and 221.0 nm (formulation T2P1). Finally, with double
coating with Tween 80 and PEG 20000 up to 2%, mean particle size of the
double-coated formulations increased from 154.5 nm (formulation T0P0) to 203.6
nm (formulation T1P1) and 276.2 nm (formulation T2P2). This could be
attributed to the presence of Tween 80 facilitating the hydrogen bond formation
with incoming PEG 20000 as a double coating, forming a layer-wise coherent
coating over doxorubicin-loaded PBCA-NPDS (148). On the other hand, the
mean particle size slightly increased from 256.9 nm (formulation T1P2) to 276.2
nm (formulation T2P2). Therefore, it can be concluded that an overcoating with
high molecular weight of PEG may impact the particle size of doxorubicin-loaded
PBCA-NPDS. Additionally, a low PdI value < 0.2 was observed for all
formulations (Table 2). This could be attributed to serial filtration step employed
during the preparation and isolation of nanoparticles from reaction medium. A
low PdI (≤0.2) is generally deemed acceptable when selecting polymeric
nanoparticles as a delivery system (149).
The mean zeta potential of placebo was observed to be -3.09 mV and for
different formulations zeta potential values varied from 2.72 to 5.29 mV (Table
2). PBCA-NPDS have an inherent negative zeta potential, due to the resonance
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stabilized negative charge formed during the polymerization step (150).
Interestingly, the zeta potential of uncoated doxorubicin loaded PBCA-NPDS
(formulation T0P0) showed a positive shift in zeta potential following the
addition of doxorubicin as compared to the blank PBCA-NPDS (3.13 mV vs. 3.09 mV). This shift in the zeta potential of formulations can be attributed to the
predominant positive charge of doxorubicin (pKa = 8.2) at a pH of 3.00 used
during the polymerization reaction. No significant change in zeta potential values
were observed in the presence of single- or double-coating of doxorubicin-loaded
PBCA-NPDS. This finding suggests that the coating did not impact the shear
plane of the particle, which otherwise would have resulted in shifts in zeta
potential values.
As displayed in Table 2, the entrapment efficiency of doxorubicin within
various doxorubicin-loaded PBCA-NPDS formulations varied from 86.5%
(formulation T2P1) to 89.9% (formulation T0P0). A higher entrapment of
doxorubicin (i.e., >86%) could be attributed to adding doxorubicin during the
polymerization step. Doxorubicin when added during the polymerization step may
act as a nucleophile and can form a part of the growing polymeric chain, yielding
higher entrapment within the formed nanoparticles (151).
Based on Figure 7, 1H NMR spectrum comparison reveals that the amine
group of doxorubicin is unconjugated with the PBCA during the formation of
nanoparticle. This is based on the observed multiplet splitting at a chemical shift
of about 2 ppm for both doxorubicin-loaded PBCA-NPDS (Figure 7A) and
doxorubicin (Figure 7B), respectively. As reported, a multiplet splitting of the
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peak at 2 ppm is a characteristic of doxorubicin which represents protons of the
amine group and aliphatic carbon atom (152).
5.3. In vitro drug release
5.3.1. Screening of dialysis membrane
The diffusion profile of free doxorubicin in solution across dialysis
membrane with different MWCOs is shown in Figure 8. The mean cumulative
doxorubicin diffused was 94.503% across the membrane (1000 KDa) as
compared to 91.093%, 86.543%, and 90.523% across the membrane with 50, 100,
and 300 KDa, respectively. Among various methods to study the drug release
from various nano-formulations (liposomes, nanoparticles, etc.), usage of the
dialysis membrane bag has been reviewed in the literature (131). However, the
selection criteria of a dialysis membrane bag over another is seldom reported.
Therefore, the screening of various types of dialysis membrane bags and its
impact on the diffusion rate of doxorubicin through the dialysis membrane bags
was performed, prior to in vitro drug release study. Although maximum amount
of doxorubicin diffused across the dialysis membrane bags (MWCO: 1000 KDa)
over a period of 6 hours. These results indicate that there is a delay in drug
diffusion involved when using dialysis membrane bags for drug release study.
Furthermore, an incomplete diffusion (i.e., <100%) indicates that even using the
highest MWCOs, which is generally assumed to facilitate diffusion of free drug,
may lead to an underestimation of actual drug release from the nano-formulations.
Since highest amount of drug diffused across the dialysis membrane with
MWCOs 1000 KDa, it was chosen for all future experiments.
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5.3.2. In vitro drug release study of various doxorubicin loaded PBCA-NPDS
The in vitro drug release profile of all formulations is shown in Figure 9.
All formulations showed characteristic biphasic release with an initial burst
release followed by a second phase with a much slower rate of drug release. The
initial burst release phase could be attributed to immediate desorption of
doxorubicin from the surface of PBCA-NPDS. And, the next slow phase could be
attributed to slow desorption of doxorubicin located in the interior of PBCANPDS and/or erosion of PBCA-NPDS (153). The highest amount of drug release
(i.e., 78.2%) at 72 h of release study was obtained from formulation T0P0. With
2% coating of PEG 20000 (formulation T2P2), the release rate was lowest and
was reduced to 35.7% over the same period of time. On the other hand, the release
profile of doxorubicin was different for each formulation suggesting that
doxorubicin had to diffuse through the polymer and surfactant coating employed
on the doxorubicin-loaded PBCA-NPDS. A trend of decrease in release rate with
the increase in Tween 80 or PEG 20000 coating concentration was observed. The
amount of doxorubicin release decreased from 62.5% (formulation T1P0) to
47.5% (formulation T1P1). Similarly, the amount of doxorubicin release
decreased from 59.4% (formulation T0P1) to 47.5% (formulation T1P1). Based
on this trend, it can be suspected that the outward release of entrapped
doxorubicin could be a function of coating concentration of PEG 20000, and not
so much with Tween 80. This action of high MW PEG (typically >5000 Da)
could be due to the folding of long chains of PEG. And, such folding may result
in unfavorable entropy changes, which further results in compression and stability
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of the coating layer (82). An existence of a similar sort of “release barrier” caused
by increased concentration of PEG 20000 which is impeding the drug release is
suspected. However, further surface analysis of these doxorubicin loaded PBCANPDS is needed to conform the existence of such a “release barrier”.
5.4. Drug leakage study in FaSSIF and serum
The drug leakage in FaSSIF and serum from various doxorubicin loaded
PBCA-NPDS is shown in Figure 10. As shown in Figure 10A, the mean %
doxorubicin leakage in FaSSIF after 12 hours of incubation from various
doxorubicin loaded PBCA-NPDS formulations varied from 18.9-28.6%. A trend
of reduction in drug leakage due to PEG 20000 overcoat was observed. Mean
doxorubicin leakage reduced from 21.0% (formulation T0P0) to 18.9%
(formulation T0P1). Similarly, mean doxorubicin leakage reduced from 26.8%
(formulation T1P0) to 24.5% (formulation T1P1), and further reduced to 20.8%
(formulation T1P2). Conversely, drug leakage increased with increase in coating
with Tween 80. Mean doxorubicin leakage increased from 21.0% (formulation
T0P0) to 26.8% (formulation T1P0). Similarly, mean doxorubicin leakage
increased from 24.5% (formulation T1P1) to 28.7% (formulation T2P1).
As shown in Figure 10B, the highest mean leakage of doxorubicin (i.e.,
3.5%) was observed in formulation T0P0. A trend of reduction in leakage with an
overcoating with PEG 20000 was observed. The mean doxorubicin leakage
reduced from 2.2% (formulation T1P0) to 0.3% (formulation T1P1). Further with
an overcoat with Tween 80 (i.e., double-coated formulations) had a better
protection efficacy towards unwanted drug leakage. A significant reduction (p <
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0.001) in doxorubicin leakage was observed in formulation T2P2 in comparison
to single- and un-coated formulations.
The preventing of the drug leakage form double-coated doxorubicinloaded PBCA-NPDS was observed to be resulted from the overcoating with PEG
20000. Such protective action is in line with previously published literature (154).
Therefore, to maximize the protective efficacy of PEGs, and brain targeting
potential with an overcoat with Tween 80, formulation T2P2, representing the
highest amount of Tween 80 and PEG 20000 was selected for further exploration
in in vitro cell culture model and for its biodistribution and pharmacokinetic
studies in rats.
5.5. In vitro model to elucidate the brain uptake mechanism
5.5.1. Uptake mechanism elucidation using specific inhibitors as a
pretreatment
Figure 11 illustrates the effect of various inhibitors on doxorubicin uptake
from double-coated doxorubicin-loaded PBCA-NPDS (formulation T2P2) and
doxorubicin solution (control). It can be observed that when bEnd.3 cells were
pretreated with the growth media (no pretreatment), the mean amount of
doxorubicin absorbed by cells treated with formulation T2P2 was found to be the
highest (i.e., 2.6 µg). On the other hand, when the cells were pretreated with
various inhibitors (i.e., sucrose, sodium azide, at 4°C, dynasore, and ammonium
chloride) known to inhibit specific cell uptake processes, significant reduction (p
< 0.001 in all cases) in absorption of doxorubicin by bEnd.3 cells was observed.
There are distinct internalization mechanisms for nanoparticles to enter cells

44

(155). In general, they can be divided into active and passive mechanism.
Generally nanoparticles are internalized by the cells via energy dependent
endocytosis which is influenced by temperature (such as at 4°C) under in vitro
condition (156). On the other hand, free drug is internalized via passive
mechanism. Therefore, several specific endocytic inhibitors to identify the
internalization pathways involved in the cellular uptake of formulation T2P2 by
bEnd.3 cells was evaluated in this study. Based on Figure 11, it is possible to see
the effect of each inhibitor on the doxorubicin internalization from formulation
T2P2 in comparison to doxorubicin solution. The uptake of doxorubicin from
formulation T2P2 was found to be inhibited at 4 °C and with pretreatment with
sodium azide, suggesting that their uptake was mediated by endocytosis. More
specifically, involvement of clathrin-mediated endocytosis was confirmed when
reduction in cell uptake doxorubicin from formulation T2P2, after pretreatment of
the cells with sucrose, was observed. A reduction in cell uptake of doxorubicin
from formulation T2P2, after pretreatment of the cells with dynasore, further
confirmed that Tween 80 coated PBCA-NPDS may mimic as low-density
lipoprotein (LDL) particles. In contrast, amount of doxorubicin absorbed by the
bEnd.3 cells remained relatively similar to that of without any pretreatment when
the cells were treated with doxorubicin solution (3.03 µg vs. 2.89 µg, 3.01 µg,
2.99 µg, 3.03 µg, and 2.49 µg, respectively), since the free drug is up taken by
cells solely by passive absorption mechanism (157). Upon inhibiting the specific
transporters, no significant reduction in the amount of doxorubicin absorbed by
the cells was observed. Therefore, the main mechanism involved in the uptake of
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formulation T2P2 by bEnd.3 cells was found to be LDL receptor-mediated
endocytosis. In fact, LDL receptor was found to be associated with clathrincoated pits on the cell surface, which when bound to LDL mimicking particles
form clathrin-coated vesicles in the cell (158). Finally, reduction in cell uptake of
doxorubicin from formulation T2P2, after pretreating with ammonium chloride,
suggests that formulation T2P2 may partially follow both lysosomal and
endosomal trafficking inside bEnd.3 cells, which is important for drug delivery or
drug transport through barriers (159). In fact, the lysosomal pathway is
responsible for nanoparticle degradation and subsequently release of drug content
inside cells, while the endosomal trafficking may be involved in the transport of
intact drug-loaded nanoparticles across the cell barrier. Furthermore, no cellular
toxicity (i.e., mean cell viability > 85%, n = 6) was observed when the cells were
incubated with various inhibitors at concentration levels described previously.
5.5.2. Permeability screening study
To verify the transcytosis of formulation T2P2 transport across the
monolayer on Transwell® from apical to basolateral was evaluated. The Papp
values obtained after transport experiment of formulation T2P2 in comparison to
doxorubicin solution were shown in Figure 12. The Papp (apical to basolateral) of
doxorubicin across the monolayer was significantly higher (p = 0.003), when the
monolayer was incubated with formulation T2P2 vs. doxorubicin solution (9.6 ×
10-5 cm/sec vs. 6.6 × 10-5 cm/sec). This outcome probably happened from the
interaction between ApoE adsorbed on the surface of formulation T2P2 and LDL
receptors expressed on bEnd.3 cells. On the other hand, formulation T2P2
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mediated transport of doxorubicin from basolateral to apical was lower (i.e., mean
Papp of 5.9 × 10-5 cm/sec vs. 1.2 x 10-4 cm/sec) of doxorubicin solution. In general,
efflux ratio [i.e., Papp (apical to basolateral)/Papp (basolateral to apical)] is used as a first
indication of involvement of active processes. Efflux ratio obtained from the
mean Papp values of formulation T2P2 and doxorubicin solution was observed to
be 0.6 and 1.8, respectively. Furthermore, a 3-fold reduction in doxorubicin
mediated efflux ratio was observed by formulation T2P2 from basolateral to
apical side of the monolayer. This finding is in line with the inhibitory action of
Tween 80 on efflux transporters reported elsewhere (160).
5.6. Biodistribution and pharmacokinetic studies in rats
5.6.1. Biodistribution studies
As shown in Figure 13, significant amount (p = 0.017) of doxorubicin was
available in the serum after 3 hours following oral administration of formulation
T2P2 (Figure 13A) at a dose of 70 mg/kg (group 3). This could be due to the
higher circulation time yielded by coating with PEGs. Higher circulation time
may have resulted in increased drug available in the circulation from the
formulation T2P2. Furthermore, no significant difference was observed in
doxorubicin availability in serum among other groups. Comparing the mean
values, it can be observed that the maximum amount of doxorubicin was available
in serum after oral administration of doxorubicin solution (Figure 13A). Based on
Figure 13B, significant brain accumulation of doxorubicin occurred after 1 hour
following oral administration of formulation T2P2 at dose level of 70 mg/kg
(group 3) in comparison to formulation T2P2 at dose level of 50 mg/kg (p =
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0.005) (group 2) and doxorubicin solution at dose level of 70 mg/kg (p = 0.017)
(group 4). These findings are in line with our previous studies, wherein the
maximum anti-nociceptive effect was achieved with the highest dose of
formulation T2P2 after 60 minutes of oral administration (6). Also, as expected,
although insignificant, higher brain accumulation of doxorubicin occurred after
intravenous administration and a trend of exposure-time relationship was
observed. Based on Figure 13C, as expected, significant accumulation of
doxorubicin occurred in liver after 1 hour following intravenous or oral
administration of formulation T2P2 (p = 0.027) (groups 1-3) in comparison to
doxorubicin solution (group 4). This situation can be summarized by suggesting
that the liver acts as a reservoir of doxorubicin-loaded PBCA-NPDS, facilitating
their rapid first-phase disappearance from the blood and their second-phase
release in the body under degraded and/or excretable forms (151). Intrahepatic
distribution studies demonstrate that Kupffer cells are the major liver site of
accumulation of PACA nanoparticles (161). And, endocytosis plays a major role
in the uptake process of these nanoparticles (162). Once up taken by the liver,
nanoparticles may have metabolized with a sustained release of the drug from
tissues, which is in agreement with previously published reports on PBCA-NPDS
as drug carriers (163,164). Since this investigation using an in vitro cell culture
model also demonstrated involvement of endocytosis mechanism. The same
processes involved in the fate of the formulation T2P2 in liver was suspected. On
the other hand, doxorubicin solution was rapidly degraded and eliminated from
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the body, which further verify the findings from the pharmacokinetics studies to
be described below.
5.6.2. Pharmacokinetic studies
Figure 14 illustrates the observed and the fitted pooled serum doxorubicin
concentration-time curves of formulation T2P2 obtained after simultaneous model
fitting. As shown in Figure 14A and 14B, the serum doxorubicin concentrationtime profiles, after intravenous and oral administration of formulation T2P2, were
adequately fitted by the 2-compartment model (Equations 3 and 4). On the other
hand, 2-compartment model was not operative for describing the data obtained
after oral administration of doxorubicin solution. This could be attributed to the
faster clearance of the doxorubicin from the circulation as observed from the rapid
decline of the serum concentration (Figure 14A). Comparison of the dosage-form
related parameters (i.e., absorption rate and lag time of absorption), formulation
T2P2 exhibited a higher absorption rate of 0.05 min-1 and 0.08 min-1 at 50 mg/kg
and 70 mg/kg, respectively. On the other hand, the absorption rate of doxorubicin
solution was found to be 0.003 min-1. This could be due to the absorption
enhancement efficacy of the formulation T2P2. Furthermore, the lag time of
absorption value of formulation T2P2 was higher (i.e., 3.3-fold) as compared to
that of doxorubicin solution. A higher lag time of absorption value obtained by
formulation T2P2 indicates a delayed absorption of the formulation. This can be
attributed to an intrinsic delay in nanoparticles entry into the lymphatics (165).
Reliability of the estimated parameters were determined by comparing the
magnitude of the coefficient of variance associated with the parameters. Although
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there are no magic cut-offs, a lower value of coefficient of variance is sought for
determining the reliability of the parameter estimates. A comparatively higher
coefficient of variance associated with doxorubicin solution could be due to the
inability of the 2-compartment to explain the observed data.
5.7. In vitro cell culture studies
To investigate the uptake of double-coated doxorubicin-loaded PBCANPDS, intracellular accumulation of doxorubicin within SW620 cells, based on
its characteristic red fluorescence, was determined, and shown in Figure 15. And,
for the comparison of outcomes shown in Figure 15, the corresponding corrected
total cell fluorescence values, are calculated and represented in Figure 16.
As shown in Figure 15, doxorubicin-associated fluorescence occurred
mainly in the nuclei of the SW620 cell line for all doxorubicin-loaded PBCANPDS formulations (Figure 15a-g) and free doxorubicin (Figure 15h). Based on
the calculated corrected total cell fluorescence values shown in Figure 16, a trend
of increase in mean fluorescence intensity with an increase in the concentration of
Tween 80 was observed. Formulation T2P2 significantly increased (p < 0.001)
increased the accumulation of doxorubicin in comparison to formulations T1P1
and T2P1. Furthermore, no significant difference was observed in the
fluorescence intensity between formulation T2P2 and free doxorubicin solution.
This finding could be attributed to the sensitivity of the cell line toward treatment
with doxorubicin. Since SW620 cells do not overexpress P-gp transporters,
doxorubicin could readily access the cells and the rate of drug efflux is also
reduced.
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In addition to the SW620 cell line, intracellular accumulation of various
doxorubicin-loaded PBCA-NPs formulations were performed with the AD300
cell line. The characteristic red fluorescence and corresponding corrected total
cell fluorescence values are shown in Figure 17 and 18, respectively. Similarly, to
SW620 cells, all doxorubicin-loaded PBCA-NPs formulations resulted in
increased fluorescence intensity within AD300 cells (Figure 17a-g). On the other
hand, as expected, no nuclei accumulation was observed, when cells were treated
with free doxorubicin. Instead, the fluorescence signal was observed on the cell
membranes (Figure 17h). This could be due to over-expressed P-gp on AD300
cells, which did not allow doxorubicin accumulation in the nuclei (166). In
comparison, the intracellular localization of doxorubicin in AD300 cells treated
with formulations T2P1 (Figure 17f), and T2P2 (Figure 17g) exhibited the highest
intensity. As shown in Figure 18, formulation T2P2 exhibited the significantly
higher (p < 0.001) intensity as compared to formulations T0P1, T1P0, T1P1,
T1P2 as well as free doxorubicin, indicating enhanced retention of doxorubicin
within AD300 cells. These findings are in line with the inhibitory action of Tween
80 on over-expressed P-gp receptors due to the higher drug retention within
AD300 cells.
The cytotoxicity profiles of doxorubicin-loaded PBCA-NPs formulations
from MTT assays performed on SW620 and AD300 cell lines are illustrated in
Figure 19 and 20, respectively. For the comparison of the cytotoxicity profiles,
IC50 values (i.e., half-maximal inhibitory concentration) were calculated and
displayed in Table 3. The IC50 values of free doxorubicin in SW620 and AD300
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cell lines were 0.094 µM and 4.796 µM, respectively. Interestingly, it was
observed that double-coated doxorubicin-loaded PBCA-NPs (specifically
formulation T2P2) showed significantly higher (p < 0.001) cytotoxicity than free
doxorubicin, single-coated (formulation T0P1) (p < 0.001), and un-coated
(formulation T0P0) (p = 0.004) in AD300 cell line. These results suggest that
double-coated PBCA-NPs, specifically, formulation T2P2 have improved
anticancer property in doxorubicin resistant AD300 cells. A trend of higher
cytotoxicity with increased concentration of coating with Tween 80 was observed.
This trend could be attributed to inhibition of overexpressed p-glycoprotein
transmembrane receptors by Tween 80 as previously reported. On the other hand,
synergistic effect on cytotoxicity in AD300 cell line was observed with doublecoated doxorubicin-loaded PBCA-NPs with Tween 80 and PEG 20000. Trend
analysis of the synergistic effect indicates that overcoating with PEG 20000 might
aid in partial reversal of resistance, which could be attributed to folding of high
molecular weight PEG (> 5000 Da) presenting a barrier comprising of
conformationally random molecular chains to prevent drug efflux. This partial
resistance reversal action of doxorubicin-loaded PBCA-NPs formulations was
determined by calculating the resistance fold (i.e., ratio of IC50 values obtained in
AD300 cells to those obtained in SW620 cells). As shown in Table 3, a reduction
in doxorubicin mediated resistance on AD300 cell line treated with formulation
T2P2 as compared to doxorubicin solution was identified (22.445-fold versus
51.020-fold) indicating that double-coating with Tween 80 and PEG 20000 on
PBCA-NPs may potentiate the sensitivity of the resistant cells towards
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doxorubicin. However, no significant change in IC50 values was observed when
SW620 cells were treated with free doxorubicin in solution or formulation T2P2.
This is based on the assumption that, incorporating doxorubicin within the
nanoparticle will not impact its efficacy. Since IC50 is a drug related parameter,
we anticipate it to be similar.
The cytotoxicity profiles of doxorubicin-loaded PBCA-NPs formulations
from MTT assays performed on H460 and BCRP-overexpressed MX20 cells are
shown in Figure 21 and 22, respectively. And, IC50 values were calculated and
compared in Table 4. The IC50 values of free doxorubicin within H460 and MX20
cell lines were 0.058 µM and 0.813 µM, respectively. It was observed that
double-coated doxorubicin-loaded PBCA-NPs (formulation T1P1) showed
significantly higher (p < 0.001) cytotoxicity (about 1-fold) than free doxorubicin
in comparison to single-coated PBCA-NPs (formulation T0P1) resulting in partial
reversal by about 3.5-fold. These results suggest that these double-coated PBCANPs formulations might have improved anticancer property in mitoxantrone
resistant MX20 cells. A similar trend (with respect to SW620 and AD300 cells) of
higher cytotoxicity with increased concentration of overcoating with Tween 80
was observed. Consequently, formulation T2P2, exhibited significantly higher
cytotoxicity in comparison to formulation T1P1. This finding suggests that an
overcoat of Tween 80 at 2% might be required for enhanced cytotoxicity of
formulations in resistant cells. Further, this trend could be attributed to inhibition
of overexpressed BCRP transmembrane transports by Tween 80 as previously
reported (167). On the other hand, synergistic effect on cytotoxicity in MX20 cell
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line was observed with double coating of doxorubicin-loaded PBCA-NPs
formulations with Tween 80 and PEG 20000. Trend analysis of the synergistic
effect indicates that overcoating with PEG 20000 may also aid in partial reversal
of resistance, which could be attributed to folding of high molecular weight PEG
(20000 Da in this case) is presenting a barrier comprising of conformationally
random molecular chains to prevent drug efflux (168). Furthermore, based on the
calculated resistance fold value (Table 4), it can be observed that formulation
T2P2 is also able to potentiate the sensitivity of doxorubicin in the mitoxantrone
mediated resistant cell line (i.e., MX20), wherein the reduction of resistance from
13.943-fold (i.e., doxorubicin solution) to 4.851-fold was observed. However,
contrary to their enhanced efficacy towards the resistant cell line, lower
cytotoxicity (higher IC50 values) as compared to doxorubicin solution for all
doxorubicin-loaded PBCA-NPs formulations was observed in H460 cell line,
indicating the specificity of these formulations towards the resistant MX20 cell
line. Furthermore, this difference could be attributed to variability in the
availability of doxorubicin at the cellular level. For example, free doxorubicin is
instantly available within the cells, whereas, with nanoparticles time dependent
drug release also needs to be taken into consideration.
6. Conclusion
In has been reported that an overcoat with PEG 20000 coating enhanced
the stability of this formulation in the gastrointestinal tract. And, a particle size of
less than 300 nm could have influenced the M-cells mediated uptake of these
formulation, and its subsequent transport into the systemic circulation. On the
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other hand, Tween 80 coating facilitated the adsorption of ApoE from the
circulation and subsequently facilitated the brain delivery of PBCA-NPDS by
LDL receptor mediated endocytic uptake across the BBB. As a result, doublecoated doxorubicin PBCA-NPDS (formulation T2P2) was observed cross the
gastrointestinal barrier after oral administration and still retain its targeting
properties to the brain. Furthermore, under in vitro conditions Formulation T2P2,
exhibited enhanced cytotoxicity and specificity towards the P-gp and BCRP
overexpressing cell lines. Similar to in vivo studies the success of double-coated
PBCA-NDs can be hypothesized due to interplay of a number of factors
simultaneously. They could be (a) particle size less than 300 nm, and (b) double
coats of Tween 80 and PEG 20000. The particle size of the formulation could
have helped in endocytic uptake of the nanoparticles across the cell barrier. The
action of double-coats of Tween and PEG are suspected to play the following
roles. The role of Tween 80 and PEG 20000 coating had been the enhancement of
accumulation of doxorubicin from double-coated PBCA-NPDS (formulation
T2P2) in both P-gp and BCRP overexpressing cell lines. Hence, we can conclude
that, the application of the double-coated PBCA-NPDS with overcoats of Tween
80 and PEG 20000 could be feasible approach to deliver and target doxorubicin to
brain via the oral route and aid in overcoming MDR.
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7. Tables
Table 1: Physiochemical characterization methods for nanoparticles
Parameter

Method

Particle size

Photon correlation spectroscopy,
Transmission electron microscopy
(TEM), Scanning electron
microscopy (SEM)

Surface charge

Electrophoresis, Laser doppler
anemometry

Crystallinity

X-ray diffraction (XRD),
Differential scanning calorimetry
(DSC)

Hydrophobicity

Hydrophobic interaction
chromatography, contact angle
measurement

Molecular weight determination

Gel chromatography
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Table 2: Formulation codes and characteristics of various doxorubicin-loaded
PBCA-NPDS. Data presented as mean ± standard deviation, n = 3.
Formulation

Codes

Particle size

PdI

(nm)

-

Placebo*

109.4 ± 3.3

0.083 ± 0.022

Zeta

%

potential

Entrapment

(mV)

efficiency

-3.09 ± 0.97

Not
applicable

Core

T0P0

154.5 ± 1.4

0.044 ± 0.039

3.13 ± 0.84

89.9 ± 0.1

Single-

T0P1

182.6 ± 25.5

0.040 ± 0.019

2.72 ± 0.94

87.0 ± 0.1

coated

T1P0

154.4 ± 5.7

0.076 ± 0.028

4.19 ± 0.78

88.3 ± 0.3

Double-

T1P1

203.6 ± 8.1

0.064 ± 0.046

5.29 ± 2.24

88.5 ± 0.1

coated

T1P2

256.9 ± 9.1

0.082 ± 0.017

3.95 ± 0.84

88.5 ± 0.4

T2P1

221.0 ± 20.0

0.129 ± 0.116

3.08 ± 2.30

86.5 ± 0.2

T2P2

276.2 ± 15.4

0.110 ± 0.062

2.75 ± 0.48

88.4 ± 0.3

* Placebo = PBCA-NPDS (blank nanoparticles)
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Table 3: The cytotoxic effect of doxorubicin and double-coated doxorubicinloaded PBCA-NPDS on SW620 and AD300 cell lines.
Treatment

SW620
IC50 ± SDa (µM)

AD300
IC50 ± SDa (µM)

RFb

Free doxorubicin

0.094 ± 0.018

4.796 ± 0.271

51.020

T0P0

0.061 ± 0.013

2.653 ± 0.125

43.491

T0P1

0.068 ± 0.012

2.700 ± 0.066

39.705

T1P0

0.073 ± 0.004

1.857 ± 0.464#

25.438

T1P1

0.044 ± 0.017

1.613 ± 0.161*

36.659

T1P2

0.081 ± 0.004

1.866 ± 0.082

23.037

T2P1

0.067 ± 0.023

1.775 ± 0.062

26.492

T2P2

0.074 ± 0.012

1.661 ± 0.142##

22.445

IC50: concentration that inhibited cell survival by 50%
RF: Resistance fold was the ratio of IC50 value from AD300 cells over SW620
cells, respectively for all treatments.*Statistically significant (p < 0.001) in
comparison to formulation T0P1, and #p = 0.004 in comparison to formulation
T0P0. ##p < 0.001 in comparison to free drug, and formulation T0P0 and T0P1.
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Table 4: The cytotoxic effect of doxorubicin and double-coated doxorubicinloaded PBCA-NPDS on H460 and MX20 cell lines.
Treatment

H460

MX20

IC50 ± SDa (µM)

IC50 ± SDa (µM)

RFb

Free doxorubicin

0.058 ± 0.002

0.813 ± 0.014

13.943

T0P0

0.196 ± 0.012

1.574 ± 0.097

8.019

T0P1

0.173 ± 0.012

1.597 ± 0.067

9.225

T1P0

0.112 ± 0.024

0.626 ± 0.025

5.603

T1P1

0.154 ± 0.016

0.674 ± 0.013#

4.374

T1P2

0.189 ± 0.045

0.817 ± 0.030

4.313

T2P1

0.158 ± 0.002

0.637 ± 0.011

4.038

T2P2

0.135 ± 0.023

0.653 ± 0.005*

4.851

IC50: concentration that inhibited cell survival by 50%
RF: Resistance fold was the ratio of IC50 value from MX20 cells over H460 cells,
respectively for all treatments. *Significantly lower (p = <0.001) in comparison to
formulation T1P2, and #p = <0.001 in comparison to formulation T0P1.
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8. Figures

Figure 1: Schematic representation of three possible mechanisms of
gastrointestinal uptake of surface modified poly(butyl cyanoacrylate)
nanoparticles (PBCA-NPDS).

Represents surface modified PBCA-NPDS: (a)

intracellular uptake (via intra-epithelial lymphatics, IELs); (b)
intracellular/paracellular uptake; (c) uptake via the M-cells and Peyer’s patches in
the gut lumen. Adapted from reference (1) with modifications.
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Figure 2: Schematic representation pathway of doxorubicin delivery to the brain
facilitated by double-coated doxorubicin-loaded PBCA-NPDS after oral
administration: (a) doxorubicin efflux in the lumen facilitated by the P-gp
receptor in the duodenum following either intracellular and/or paracellular uptake
by the duodenum, (b) uptake of double-coated doxorubicin-loaded PBCA-NPDS
via the M-cells of the Peyer’s patches of the ileum, and (c) LDL-receptor
mediated transcytosis of the double-coated doxorubicin-loaded PBCA-NPDS
from blood lumen into the brain.
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Figure 3: Schematic representation of nanoparticle formulation. (A) doxorubicinloaded PBCA-NPDS (core), (B) Tween 80 overcoated nanoparticles, and (C)
Tween 80 and PEG 20000 overcoated nanoparticles. Adapted from reference (67)
with modifications.
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Figure 4: Calibration curve of doxorubicin assayed by the UV-Vis spectroscopy
method (R2 = 0.9996, n = 6).
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Figure 5: Calibration curve of doxorubicin assayed by the fluorescence
spectroscopy (plate-reader method) spiked in various medium (R2 > 0.995 in each
case , n = 6).
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Figure 6: Fluorescence microscopy images of cells for method selection. A) cell
nuclei stained DAPI, B) cells treated with free doxorubicin, exhibiting
characteristic red fluorescence associated with doxorubicin within the cell, and C)
merged image of the cells is depicted by an arrow. (Scale bar: 10 µm).
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a)

b)

Figure 7: 1H NMR of spectrums of a) doxorubicin-loaded PBCA-NPDS, and b)
free doxorubicin in DMSO-d6. Arrow shows a characteristics peak for the protons
associated with amine and aliphatic carbon atom (boxed in the chemical
structure).

66

Cummulative doxorubicin released (%)

100

80

60

40

50 KDa
100 KDa
300 KDa
1000 KDa

20

0
0

1

2

3

4

5

6

Time (h)

Figure 8: Comparison of diffusion profiles of free doxorubicin using different
MWCO dialysis membranes in the release medium at 37° ± 0.5°C, 100-120 rpm.
(Data are presented as mean ± standard deviation, n = 3).
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Figure 9: In vitro drug release profiles of various doxorubicin-loaded PBCANPDS (Data presented as mean ± standard deviation, n = 3).
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Figure 10: % Doxorubicin leakage from various doxorubicin-loaded PBCANPDS after 12 hours incubation period in a) FaSSIF, and b) Serum at 37° ± 0.5°C
and 100–120 rpm. (Data presented as mean ± standard deviation, n = 3).
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Figure 11: The in vitro model in which bEnd.3 cells were subjected to various
inhibitors as pretreatments, and then followed with treatment of formulation T2P2
or doxorubicin solution for additional 3 hours of cell incubation for elucidation of
the brain uptake mechanism (data presented as mean ± standard deviation, n = 6).
* Significantly (p < 0.001) reduced uptake of doxorubicin in bEnd.3 cells
pretreated with various inhibitors.
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Figure 12: Apparent permeability (Papp) after transport experiment of formulation
T2P2 or doxorubicin solution across bEnd.3 cells monolayer after 2 hours
incubation period (data presented as mean ± standard deviation, n = 3). *p = 0.003
and #p = 0.004 of doxorubicin permeation (higher) and efflux (lower) mediated
by formulation T2P2, from apical to basolateral and basolateral to apical side,
respectively, in comparison to doxorubicin solution.
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a)

b)

c)

Figure 13: Biodistribution of doxorubicin in a) serum, b) brain, and c) liver from
formulation T2P2 after intravenous administration (group 1) and oral
administration (groups 2-3), in comparison to oral doxorubicin solution (data
present mean ± standard deviation, n = 2). *p = 0.017 in comparison to 1 hour,
#p = 0.005 in comparison to group 2 at 1 hour, ##p = 0.017 in comparison to
group 4 at 1 hour, and ˠp = 0.027 in comparison to groups 1-3 after 3 hours.
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a)

b)

c)

Figure 14: Simultaneous model fitting of pooled doxorubicin serum
concentration-time profiles after intravenous administration of formulation T2P2
(27 mg/kg), respectively, with a) oral administration of T2P2 (50 mg/kg), b) oral
administration of T2P2 (70 mg/kg), and c) oral administration of doxorubicin
solution (70 mg/kg).
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Figure 15: Fluorescence associated with intracellular accumulation of doxorubicin
within human colon adenocarcinoma cell line SW620, following treatment with,
(a) T0P0, (b) T0P1, (c) T1P0, (d) T1P1, (e) T1P2 (f) T2P1, (g) T2P2, (h) Free
doxorubicin, and (i) No treatment. Note: Arrows represent the accumulation of
doxorubicin in the nucleus. (Magnification: 40×, Scale bar: 10 µm).
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Figure 16: The values of calculated corrected total cell fluorescence intensity
within SW620 cells, based on the outcomes shown in Figure 15 (data presented as
mean ± standard deviation, number of cells counted = 50, *p = < 0.001).
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Figure 17: Fluorescence detection upon the intracellular accumulation of
doxorubicin in doxorubicin-resistant human colon adenocarcinoma cell line
AD300, following treatment with, (a) T0P0, (b) T0P1, (c) T1P0, (d) T1P1, (e)
T1P2 (f) T2P1, (g) T2P2, (h) Free doxorubicin, and (i) No treatment. Arrows
represent the accumulation of doxorubicin in the nucleus. (Magnification: 40×,
Scale bar: 10 µm).
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Figure 18: The values of calculated corrected total cell fluorescence intensity
within AD300 cells, based on the outcomes shown in Figure 17 (data presented as
mean ± standard deviation, number of cells counted = 30, *p = < 0.001).
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Figure 19: Concentration dependent cytotoxicity profile obtained after treating
SW620 cell lines with various doxorubicin-loaded PBCA-NPDS in comparison
with free doxorubicin. Data presented as mean ± standard deviation, and
representative of three independent experiments in triplicate are shown.
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Figure 20: Concentration dependent cytotoxicity profile obtained after treating
AD300 cell line with various doxorubicin-loaded PBCA-NPDS in comparison
with free doxorubicin. Data presented as mean ± standard deviation, and
representative of three independent experiments in triplicate are shown.
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Figure 21: Concentration dependent cytotoxicity profile obtained after treating
H460 cell line with various doxorubicin-loaded PBCA-NPDS in comparison with
free doxorubicin. Data presented as mean ± standard deviation, and representative
of three independent experiments in triplicate are shown.
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Figure 22: Concentration dependent cytotoxicity profile obtained after treating
MX20 cell line with various doxorubicin-loaded PBCA-NPDS in comparison with
free doxorubicin. Data presented as mean ± standard deviation, and representative
of three independent experiments in triplicate are shown.
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